About Us
AHEAD Medicine is transforming healthcare through innovative AI technology. Our flagship Cyto-copilot platform employ AI to streamline the flow cytometry data analysis workflow. Cyto-copilot empowers healthcare providers to deliver faster, more consistent, standardized and scalable results for disease diagnosis, patient monitoring, and cell therapy quality control.
Mission Statement
At AHEAD, our mission is to enhance healthcare equity and address the shortage of healthcare professionals through groundbreaking data analysis solutions. We are committed to delivering fast, accurate, consistent, and scalable systems that drive better patient outcomes. By pioneering advanced healthcare technologies, we aim to shape a more innovative, efficient, and accessible future for the ealhtcare industry.
Core Leadership
Andrea Wang, co-founder and CEO of AHEAD Medicine Corporation, is a recognized leader at the intersection of entrepreneurship, medicine, and data science. A cancer survivor with a visionary outlook for healthcare, Andrea's expertise is shaped by her academic tenure at Baylor College of Medicine and her impactful roles in the pharmaceutical industry. Since co-founding AHEAD in 2017 with Kevin and Jeremy, she has guided the company through global challenges, establishing it as a pioneer in healthcare innovation. Andrea's scientific contributions have been featured in leading journals and the prestigious Flow Cytometry Protocol 5th Edition by Springer. She holds multiple patents integral to AHEAD's groundbreaking technology. Her commitment to leveraging AI in healthcare aims to transform patient care worldwide. In recognition of her innovations, Andrea was selected as an International Innovator by the International Society for Advancement of Cytometry (ISAC) Leadership Development Program in 2024. She currently leads both the FCS4.0 workshop initiatives and CYTO Innovation within ISAC, driving advancement in the field of cytometry.
Kevin Ko, co-founder and Chief Medical Advisor of AHEAD Medicine, is a distinguished hematologist with dual M.D. and Ph.D. degrees from National Taiwan University (NTU). His expertise spans the breadth of hematological disorders and the economic aspects of healthcare. Currently serves as the President of the Hematology Society of Taiwan, Dr. Ko also directs the Department of Hematological Oncology at NTU Cancer Center, and the Tai-Chen Cell Therapy Center, where he oversees leading-edge treatments like CAR T-cell therapy. Renowned for his clinical excellence and research, Dr. Ko has significantly influenced healthcare practices in Taiwan and the Asia-Pacific region, particularly in leukemia care and stem cell transplantation. His distinguished career and leadership are vital to AHEAD Medicine's mission to innovate and revolutionize healthcare and biomedical research.
Jeremy Lee, a co-founder of AHEAD Medicine and a distinguished electrical engineer, holds a Ph.D. from the University of Southern California (USC). He is a faculty member at National Tsing Hua University (NTHU), where he also co-chairs the nVIDA Innovation Center and directs the BIIC lab, advancing research in speech technology and health analytics. A senior member of IEEE, Jeremy's contributions have been recognized with several honors, including the prestigious 2024 National Science and Technology Council Outstanding Research Award. At AHEAD Medicine, he harnesses his machine learning expertise to spearhead the development of Cyto-copilot and other AI-enabled data analysis solution within AHEAD, significantly strengthening AHEAD's patent portfolio.